4th ADC Toxicity Summit

Memo

As ADC pipelines continue to grow rapidly, toxicity remains one of the biggest barriers to clinical success, patient safety, and regulatory approval. Recent safety setbacks across major ADC programs have intensified industry focus on improving toxicity prediction, translational safety assessment, and dose optimization strategies. Returning in 2026, the 4th ADC Toxicity Summit is the only dedicated industry forum exclusively focused on preventing, predicting, and mitigating ADC toxicities across preclinical and clinical development. Bringing together toxicologists, translational scientists, pharmacologists, clinicians, and safety leaders from pharma, biotech, and academia, this summit offers a highly focused and collaborative environment to address the industry’s most urgent safety challenges. Across interactive workshops, technical case studies, panel discussions, and networking sessions, attendees will explore advanced in vitro and in vivo models, FDA New Approach Methodologies (NAMs), translational biomarkers, ILD and ocular toxicity management, and safety strategies for next-generation ADCs including dual payloads and bispecifics. With increased regulatory scrutiny and growing pressure to accelerate safer ADCs to patients, this is the must-attend event for anyone committed to improving ADC tolerability, reducing patient risk, and advancing clinically successful ADC programs. URLsTickets: https://go.evvnt.com/3643048-2?pid=5569 Brochure: https://go.evvnt.com/3643048-3?pid=5569  Date and Time: Tue, 25 Aug 2026 08:00 - Thu, 27 Aug 2026 18:00 Venue details: Revere Hotel Boston Common, 200 Stuart St, Boston, Massachusetts, 02116, United States   Prices:Drug developer Pricing - 3 Day Pass: USD 4397.00,Drug Developer Pricing - Conference Only: USD 3099.00,Academic Pricing - 3 Day Pass: USD 3797.00,Academic Pricing - Conference Only: USD 2699.00,Service Provider Pricing - 3 Day Pass: USD 5297.00,Service Provider Pricing - Conference Only: USD 3799.00 Speakers: Oluwadamilola Ogunyankin, Senior Medical Director, Abbvie, Zenta Tsuchihashi, Head Senior Director, Translational Safety, Clinical Safety and Pharmacovigilance, Daiichi Sankyo, Kazuyoshi Kumagai, Senior Director, Daiichi Sankyo, Kwasi Amofa, Scientist Translational DMPK Sciences, Johnson and Johnson, Ganesh Swaminathan, Principal Scientist, Pfizer, Philip Moquist, Director in ADC Chemistry, Pfizer, Rakesh Dixit, President and Chief Executive Officer, Bionavigen, Jutta Deckert, Vice President, Research and Development, Iksuda Therapeutics, Rodrigo Ruiz-Soto, Chief Medical Officer, LigaChem Biosciences, Michael Weickert, Chief Executive Officer, Pacylex Pharmaceuticals, Inc., Doo Young Jung, Founder and Chief Executive Officer, Pinot Bio, Inc., Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies, Meabh O’Hare, Fellow of Neurology, Brigham and Women's Hospital, Elad Sharon, Director of Clinical, Translational and Immunotherapy Toxicity Program, Dana-Farber Cancer Institute, Jae You, Instructor in Ophthalmology, Harvard Medical School, Mauricio Garcia-Atance, Program Director, Hanson Wade